SPRO - Spero Therapeutics, Inc.
| Previous close | 1.7400 |
| Open | 1.7400 |
| Bid | 1.7800 x 800 |
| Ask | 1.7900 x 1400 |
| Day's range | 1.7400 - 1.8000 |
| 52-week range | 0.6800 - 3.1800 |
| Volume | |
| Avg. volume | 561,233 |
| Market cap | 94.629M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings date | 08 Aug 2023 - 14 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 25, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to two n
Simply Wall St.Time To Worry? Analysts Are Downgrading Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Outlook
Today is shaping up negative for Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders, with the analysts delivering a...
ZacksSpero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 28.57% and 3.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update
Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr program expected mid-year 2023; initiation of Phase 3 trial in complicated urinary tract infection (cUTI) expected in 2H 2023 Conference call and webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stag
- GlobeNewswire
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an u
- GlobeNewswire
Spero Therapeutics to Present at Upcoming Investor Conference
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Spero’s management team will present and be available for one-on-one meetings at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York
- Simply Wall St.
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders are no doubt pleased to see that the share price has bounced 26...
- GlobeNewswire
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023, in Copenhagen, Denmark.
- Simply Wall St.
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Shareholders in Spero Therapeutics, Inc. ( NASDAQ:SPRO ) may be thrilled to learn that the analysts have just delivered...
- Simply Wall St.
Spero Therapeutics (NASDAQ:SPRO) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
ZacksSpero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update
Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr provided Spero with $66 million upfront, a $9 million direct equity investment, and eligibility for future milestone payments and tiered royalties Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a mu
- GlobeNewswire
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has changed the date of its previously announced 2022 fourth quarter and full year earnings release and conference call from today, Monday, March 13, 2023 to
- GlobeNewswire
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and
- GlobeNewswire
Spero Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 43r
ZacksDown -12.5% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
Spero Therapeutics, Inc. (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksSpero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Spero Therapeutics, Inc. (SPRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Simply Wall St.
Spero Therapeutics (NASDAQ:SPRO) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 85%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders should be happy to see the share price up 18% in the last month...
- GlobeNewswire
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one me
- Simply Wall St.
Spero Therapeutics Third Quarter 2022 Earnings: Misses Expectations
Spero Therapeutics ( NASDAQ:SPRO ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.01m (down 35% from 3Q...
ZacksSpero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of common stock, with potential for future milestone payments and tiered royalties Initiation of a placebo-controlled Phase 2 trial designed to provide clinical proof-of-concept for SPR720 in nontuberculous mycobacterial pulmonary disease with top line results expected in 1H 2024 Conference call and live we
- GlobeNewswire
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future milestone payments and tiered royaltiesCAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare
- GlobeNewswire
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide
ZacksSpero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?
Spero Therapeutics, Inc. (SPRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
